Meeder Asset Management Inc. increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 175.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,951 shares of the company’s stock after acquiring an additional 1,880 shares during the period. Meeder Asset Management Inc.’s holdings in Zoetis were worth $213,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado grew its holdings in Zoetis by 41.6% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 1,207,018 shares of the company’s stock worth $86,954,000 after acquiring an additional 354,786 shares during the period. CIBC Asset Management Inc boosted its position in Zoetis by 5.7% during the fourth quarter. CIBC Asset Management Inc now owns 60,398 shares of the company’s stock worth $4,351,000 after purchasing an additional 3,280 shares in the last quarter. Wrapmanager Inc. purchased a new position in Zoetis during the fourth quarter worth approximately $339,000. Checchi Capital Advisers LLC purchased a new position in Zoetis during the fourth quarter worth approximately $230,000. Finally, SeaCrest Wealth Management LLC purchased a new position in Zoetis during the fourth quarter worth approximately $538,000. 93.73% of the stock is currently owned by hedge funds and other institutional investors.
ZTS has been the topic of a number of recent analyst reports. Cowen set a $80.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. Jefferies Group reiterated a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. BidaskClub upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $73.72.
Zoetis Inc (NYSE:ZTS) opened at $72.35 on Monday. The firm has a market capitalization of $35,260.00, a P/E ratio of 38.08, a PEG ratio of 1.60 and a beta of 1.07. Zoetis Inc has a 1 year low of $52.00 and a 1 year high of $80.13. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Thursday, January 18th. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is 26.32%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.